It was a pleasure to speak with Professor Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss his post hoc analysis of the LILAC clinical trial, investigating BIIB059 in participants with systemic lupus erythematosus (NCT02847598).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study.’ (ABSTRACT NUMBER: 1747) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- What is BIIB059 and what is the rationale for its use in the treatment of patients with systemic lupus erythematosus? (0:15)
- Could you give us a brief overview of the LILAC clinical trial and its findings? (1:01)
- What was the rationale for this post hoc analysis, and what definitions of joint manifestations were used? (2:08)
- What were the findings of the analysis? (3:12)
- What will be the next step in the clinical development of BIIB059 in this indication? (4:57)
Disclosures: Ronald Van Vollenhoven discloses research support (institutional grants): BMS, GSK, Lilly, UCB; support for educational programs (institutional grants): Pfizer, Roche; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB; speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
